Here’s why Eli Lilly will sell a generic insulin
Indianapolis-based pharmaceutical company Eli Lilly announced Monday that it will sell a generic version of Humalog, its branded insulin product. The generic will cost $137 per vial, or half as much as Humalog. Lilly’s move is seen as a partial concession to lawmakers who have grilled pharma companies about the high cost of life-saving prescription drugs. But the company will keep Humalog at its current price. Why this two-tiered drug strategy?
Click the audio player above to hear the full story.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.
